Nextgen Healthcare (NASDAQ:NXGN) updated its FY19 earnings guidance on Tuesday. The company provided EPS guidance of $0.70-$0.74 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.74. The company issued revenue guidance of $525-$535 million, compared to the consensus revenue estimate of $541.60 million.
A number of research firms recently commented on NXGN. KeyCorp decreased their price target on Nextgen Healthcare from $17.00 to $16.00 and set an underweight rating on the stock in a research report on Wednesday. Cantor Fitzgerald decreased their price target on Nextgen Healthcare from $26.00 to $23.00 and set an overweight rating on the stock in a research report on Wednesday.
NASDAQ NXGN traded down $4.76 during trading hours on Wednesday, reaching $14.85. 71,220 shares of the company’s stock were exchanged, compared to its average volume of 256,041. The firm has a market cap of $1.18 billion, a PE ratio of 26.16, a price-to-earnings-growth ratio of 3.58 and a beta of 0.60. Nextgen Healthcare has a one year low of $12.24 and a one year high of $23.73. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 1.15.
About Nextgen Healthcare
NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.
Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.